newsfilter
← Earnings
Earnings Releases·

Iambic Therapeutics — Third Quarter 2026 Earnings Summary

Iambic Therapeutics launched Enchant v3, a 41-billion-parameter AI model for drug discovery, and secured new collaborations with AbbVie and Bayer, bringing its total partnership count to eight since 2024. The company reported third-quarter 2026 collaboration revenue of $11.4 million and achieved a $1.0 million milestone payment from its Takeda partnership. Clinically, updated data for the lead candidate IAM1363 showed 36% systemic and 41% intracranial response rates in heavily pretreated patients, with a registrational trial planned for 2027. Additionally, Iambic submitted an IND for its second candidate, IAM217, and expects to file for IAM-C1 in the fourth quarter of 2026, while maintaining a cash position of $252 million as of September 30, 2026.

Company
IAMBIC THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology